Abstract:BackgroundDiabetic cardiomyopathy (DCM) is a complex multifaceted disease responsible for elevated heart failure (HF) morbidity and mortality in patients with diabetes mellitus (DM). Patients with DCM exhibit subclinical diastolic dysfunction, progression toward systolic impairment, and abnormal electrophysiology. Hypoglycemia events that occur spontaneously or due to excess insulin administration threaten the lives of patients with DM-with the increased risk of sudden death. However, the molecular underpinnings of this fatal disease remain to be elucidated. Methods and ResultsHere, we used the established streptozotocin-induced DCM murine model to investigate how hypoglycemia aggravates DCM progression. We confirmed connexin 43 (Cx43) dissociation from cell-cell interaction and accumulation at mitochondrial inner membrane both in the cardiomyocytes of patients with DM and DCM murine. Here, we observed that cardiac diastolic function, induced by chronic hyperglycemia, was further aggravated upon hypoglycemia challenge. Similar contractile defects were recapitulated using neonatal mouse ventricular myocytes (NMVMs) under glucose fluctuation challenges. Using immunoprecipitation mass spectrometry, we identified and validated that hypoglycemia challenge activates the mitogen-activated protein kinase kinase (MAPK kinase) (MEK)/extracellular regulated protein kinase (ERK) and inhibits phosphoinositide 3-kinase (PI3K)/Akt pathways, which results in Cx43 phosphorylation by Src protein and translocation to mitochondria in cardiomyocytes. To determine causality, we overexpressed a mitochondrial targeting Cx43 (mtCx43) using adeno-associated virus serotype 2 (AAV2)/9. At normal blood glucose levels, mtCx43 overexpression recapitulated cardiac diastolic dysfunction as well as aberrant electrophysiology in vivo. Our findings give support for therapeutic targeting of MEK/ERK/Src and PI3K/Akt/Src pathways to prevent mtCx43-driven DCM. ConclusionDCM presents compensatory adaptation of mild mtCx43 accumulation, yet acute hypoglycemia challenges result in further accumulation of mtCx43 through the MEK/ERK/Src and PI3K/Akt/Src pathways. We provide evidence that Cx43 mislocalization is present in hearts of patients with DM hearts, STZ-induced DCM murine model, and glucose fluctuation challenged NMVMs. Mechanistically, we demonstrated that mtCx43 is responsible for inducing aberrant contraction and disrupts electrophysiology in cardiomyocytes and our results support targeting of mtCx43 in treating DCM.

Cell Death‐inducing DFFA‐like Effector C/CIDEC Gene Silencing Alleviates Diabetic Cardiomyopathy Via Upregulating AMPKa Phosphorylation

Downregulation Of Cypher Induces Apoptosis In Cardiomyocytes Via Akt/P38 Mapk Signaling Pathway

Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway

Analysis of differentially expressed genes related to the development of diabetic cardiomyopathy in the myocardium of type-2 diabetic rats

Cardioprotective Effects of Asiaticoside Against Diabetic Cardiomyopathy: Activation of the AMPK/Nrf2 Pathway.

Cardamonin protect against diabetic cardiomyopathy by activating macrophage NRF2 signaling through molecular interaction with KEAP1

Tectorigenin protects against cardiac fibrosis in diabetic mice heart via activating the adiponectin receptor 1-mediated AMPK pathway

Cardamonin Protects Against Diabetic Cardiomyopathy by Activating Macrophage NRF2 Signaling Through Molecular Interaction with KEAP1.

Hypoglycemia-Exacerbated Mitochondrial Connexin 43 Accumulation Aggravates Cardiac Dysfunction in Diabetic Cardiomyopathy

PDCD4 deficiency ameliorates left ventricular remodeling and insulin resistance in a rat model of type 2 diabetic cardiomyopathy

Icariin Ameliorates Diabetic Cardiomyopathy Through Apelin/Sirt3 Signalling to Improve Mitochondrial Dysfunction

Diabetic cardiomyopathy: role of the E3 ubiquitin ligase.

Chronic intermittent hypoxia aggravated diabetic cardiomyopathy through LKB1/AMPK/Nrf2 signaling pathway

Soluble Epoxide Hydrolase Inhibition Protected Against Diabetic Cardiomyopathy Through Inducing Autophagy and Reducing Apoptosis Relying on Nrf2 Upregulation and Transcription Activation.

Insulin-like Growth Factor-1 Improves Diabetic Cardiomyopathy Through Antioxidative and Anti-Inflammatory Processes along with Modulation of Akt/GSK-3β Signaling in Rats

GDF11 Alleviates Pathological Myocardial Remodeling in Diabetic Cardiomyopathy Through SIRT1-Dependent Regulation of Oxidative Stress and Apoptosis

ACMSD Mediated De Novo NAD+ Biosynthetic Impairment in Cardiac Endothelial Cells As a Potential Therapeutic Target for Diabetic Cardiomyopathy.

Carvedilol Alleviates Diabetic Cardiomyopathy in Diabetic Rats.

Impaired SERCA2a Phosphorylation Causes Diabetic Cardiomyopathy Through Impinging on Cardiac Contractility and Precursor Protein Processing

Pharmacologic Activation of Angiotensin-Converting Enzyme II Alleviates Diabetic Cardiomyopathy in db/db Mice by Reducing Reactive Oxidative Stress

Abstract 279: Stromal Cell-derived Factor-1 Prevents from Diabetic Cardiomyopathy Via Cxcr7/ampk-mediated Nrf2 Activation in Type 2 Diabetic Mice